Literature DB >> 22843182

Value of a new post-procedural intravascular ultrasound score in predicting target vessel revascularization after coronary drug-eluting stents implantation.

Kai Xu1, Ya-ling Han, Quan-min Jing, Shou-li Wang, Ying-yan Ma, Xiao-zeng Wang, Geng Wang, Zu-lu Wang.   

Abstract

OBJECTIVE: There is no simple or feasible post-procedural intravascular ultrasound (IVUS) score to predict major adverse cardiac events (MACE) in patients undergoing drug-eluting stents (DES) implantation. The aim of this study is to validate a new IVUS score for predicting MACE.
METHODS: A total of 295 patients (with 322 lesions) were enrolled. IVUS score was calculated in each lesion based on five IVUS morphological characteristics: inflow/outflow disease, malapposition, underexpansion, tissue protrusion, and edge dissection (iMUTE score). We assigned two points to an underexpansion and one point for each presence of other factors. Patients were divided into low score (iMUTE score<2, n=137) and high score (iMUTE score≥2, n=158) groups.
RESULTS: At one year follow-up, a trend was seen in favor of the low iMUTE score group in MACE (3.65% vs. 10.10%; P=0.052), and there was more target vessel revascularization (TVR) in the high iMUTE score group compared with low score group (6.96% vs. 1.46%; P=0.044). Low iMUTE score was an independent predictor of freedom from TVR at one year (adjusted hazard ratio (HR) 0.5, 95% confidence interval (CI) 0.1-0.8; P=0.02).
CONCLUSIONS: Post-procedural IVUS iMUTE scoring was simple and feasible in clinical practice, and can provide independent prognostic value for TVR in patients undergoing DES implantation.

Entities:  

Mesh:

Year:  2012        PMID: 22843182      PMCID: PMC3411095          DOI: 10.1631/jzus.B1201002

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  14 in total

1.  Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study.

Authors:  Kenichi Fujii; Stéphane G Carlier; Gary S Mintz; Yi-ming Yang; Issam Moussa; Giora Weisz; George Dangas; Roxana Mehran; Alexandra J Lansky; Edward M Kreps; Michael Collins; Gregg W Stone; Jeffrey W Moses; Martin B Leon
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

2.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Authors:  Matthias Pfisterer; Hans Peter Brunner-La Rocca; Peter T Buser; Peter Rickenbacher; Patrick Hunziker; Christian Mueller; Raban Jeger; Franziska Bader; Stefan Osswald; Christoph Kaiser
Journal:  J Am Coll Cardiol       Date:  2006-11-02       Impact factor: 24.094

3.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

4.  Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation.

Authors:  Cheol Whan Lee; Su-Jin Kang; Duk-Woo Park; Seung-Hwan Lee; Young-Hak Kim; Jae-Joong Kim; Seong-Wook Park; Gary S Mintz; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

5.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.

Authors:  Joost Daemen; Peter Wenaweser; Keiichi Tsuchida; Linda Abrecht; Sophia Vaina; Cyrill Morger; Neville Kukreja; Peter Jüni; Georgios Sianos; Gerrit Hellige; Ron T van Domburg; Otto M Hess; Eric Boersma; Bernhard Meier; Stephan Windecker; Patrick W Serruys
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

6.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

Authors:  Joachim Schofer; Michael Schlüter; Anthony H Gershlick; William Wijns; Eulogio Garcia; Erick Schampaert; Günter Breithardt
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

7.  Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial.

Authors:  Shinjo Sonoda; Yoshihiro Morino; Junya Ako; Mitsuyasu Terashima; Ali H M Hassan; Heidi N Bonneau; Martin B Leon; Jeffrey W Moses; Paul G Yock; Yasuhiro Honda; Richard E Kuntz; Peter J Fitzgerald
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

8.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

9.  Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study.

Authors:  Edouard Cheneau; Laurent Leborgne; Gary S Mintz; Jun-ichi Kotani; Augusto D Pichard; Lowell F Satler; Daniel Canos; Marco Castagna; Neil J Weissman; Ron Waksman
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.